Zogenix names new board member
This article was originally published in Scrip
Executive Summary
San Diego-based Zogenix, a pharmaceutical company developing products for the treatment of pain-related conditions and central nervous system disorders, has named Dr James B Breitmeyer to its board of directors. Dr Breitmeyer currently serves as president of Bavarian Nordic, a late-stage biotechnology company. He is also executive vice-president of Bavarian A/S, a multinational corporation headquartered in Denmark which specializes in the research, development and manufacturing of vaccines and immunotherapy regimens for biodefense, infectious diseases and oncology. He has also previously served as acting chief medical officer of Zogenix in an advisory capacity.